<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745589</url>
  </required_header>
  <id_info>
    <org_study_id>A111-104</org_study_id>
    <nct_id>NCT00745589</nct_id>
  </id_info>
  <brief_title>Sevelamer Hydrochloride in Peritoneal Dialysis Patients</brief_title>
  <acronym>SERENE</acronym>
  <official_title>Use of Sevelamer Hydrochloride to Control Hyperphosphatemia and Reduce Calcification Burden in the Poor Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as
      effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression
      of cardiovascular calcification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease accounts for nearly 50% of the mortality and is the most frequent
      cause of hospitalization in ESRD patients. Hyperphosphatemia is increasingly recognized to be
      an important predictor of mortality and cardiovascular death in ESRD patients and is largely
      attributed to the increased prevalence of vascular calcification.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in coronary artery, aortic valve, mitral annulus calcium scores</measure>
    <time_frame>over 24 months</time_frame>
    <description>Vascular and valvular calcium scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in aortic pulse wave velocity</measure>
    <time_frame>over 24 months</time_frame>
    <description>arterial stiffness parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>annualized percentage change in Coronary artery calcium score</measure>
    <time_frame>over 12 months</time_frame>
    <description>annualized percentage change in calcium score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changess in serum T50</measure>
    <time_frame>over 24 months</time_frame>
    <description>serum calcification propensity measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum calcium, phosphate</measure>
    <time_frame>over 24 months</time_frame>
    <description>biochemical parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alkaline phosphatase</measure>
    <time_frame>over 24 months</time_frame>
    <description>biochemical parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intact parathyroid hormone</measure>
    <time_frame>over 24 months</time_frame>
    <description>biochemical parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in low density lipoprotein-cholesterol</measure>
    <time_frame>over 24 months</time_frame>
    <description>biochemical parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C-reactive protein</measure>
    <time_frame>over 24 months</time_frame>
    <description>biochemical parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic blood pressure</measure>
    <time_frame>over 24 months</time_frame>
    <description>blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic blood pressure</measure>
    <time_frame>over 24 months</time_frame>
    <description>blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Forearm, femur and spine bone mineral density, T score and Z score</measure>
    <time_frame>over 24 months</time_frame>
    <description>Bone mineral density related parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Endstage Renal Disease</condition>
  <arm_group>
    <arm_group_label>higher dose sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first-line higher dose sevelamer hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer hydrochloride</intervention_name>
    <description>First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)</description>
    <arm_group_label>higher dose sevelamer</arm_group_label>
    <arm_group_label>low dose sevelamer</arm_group_label>
    <other_name>Renagel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESRD patients receiving long-term peritoneal dialysis treatment with hyperphosphatemia
             currently receiving aluminum-based phosphorus binders or whose phosphorus control
             remains suboptimal with calcium-based binders only

          -  Patients who cannot afford to self-pay sevelamer hydrochloride.

          -  Patients who provided informed consent for the study

        Exclusion Criteria:

          -  Patients with underlying active malignancy

          -  Patients with cyanotic congenital heart disease

          -  Patients with poor general condition

          -  Patients with plan for living related kidney transplant within coming 1 year

          -  Female patients with pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital, Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Angela Yee-Moon Wang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>vascular,</keyword>
  <keyword>valvular calcification,</keyword>
  <keyword>phosphate binder,</keyword>
  <keyword>sevelamer,</keyword>
  <keyword>endstage renal disease</keyword>
  <keyword>peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

